focus -WSS

focus

author：hotspot 2025-10-02 18:46:29 - browse：15466

Becton Dickinson plans to pay $4.2 billion for Edwards Lifesciences’ critical care business, which sells technology that monitors the heart conditions of critically ill patients.

Edwards had told investors in December 2023 that it planned to spin off the business in order to focus more sharply on addressing structural defects in the heart. BD, meanwhile, wants to increase its monitoring presence in hospitals. In a statement announcing the acquisition, the company touted the “advanced AI algorithms” used in Edwards’ monitors.

BD CEO Tom Polen said in a statement that the acquisition will bolster BD’s portfolio of “AI-enabled clinical decision tools” and digital health products in general.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： FDA struggles to regulate food additives, sometimes for decades

hotspot

WSS

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

The system is set up to fail children with medical complexity

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

STAT Summit: Biotech founders on deal

Cigna wins case to block Amy Bricker's move to CVS

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Alkermes shareholders re

FDA warns J&J's Abiomed: We will regulate your software

Wildfire smoke exposes gaps in outdoor worker protections

Solve the antibiotic resistance crisis with preventive drugs

State Dept. review finds Biden bears some blame for Afghanistan failures

Teladoc has a new CEO, but challenges remain the same

Virginia high school admissions case could be legal follow

Statins may not be needed by millions of people, study suggests

Apple is now the first public company to be valued at $3 trillion

STAT Summit: Michael J. Fox on progress in Parkinson's research

knowledge

STAT Readout Newsletter: Today's biggest biotech updates

How faith leaders like me can help address America's obesity epidemic

Cigna wins case to block Amy Bricker's move to CVS

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Lawmakers consider Medicare pay reforms for doctors

NIH confirmation hearing shows politicization of research

focus

hotspot

Wikipedia

hotspot